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ABSTRACT 
Alzheimer's disease (AD) distresses the lives of millions of people around the 
world. Its costs were estimated to be at least l 00 billion dollars each year (Fill it, 
2000). And so far, no cure has been found to stop or slow the progression of the 
disease. Senile plaques and neurofibrillary tangles are considered to be central in 
the pathogenesis of AD. The plaques are mainly composed of aggregations of 
amyloid p (AB) peptides, which are generated upon the sequential cleavage of the 
larger amyloid precursor protein (APP) first by the enzyme P-secretase, and then 
by the enzyme y-secretase. These plaques are one of the main targets being 
explored for newer therapeutic interventions in AD. The transcription factor 
specificity protein 1 (Sp 1) is associated with the pathology of AD, as it was found 
to be involved in the transcription of APP and beta site APP cleaving enzyme l 
(BACE 1) (Christensen et al., 2004, Basha et al., 2005, Santpere et al., 2006). 
Tolfenamic acid is an NSAID that was reported to lower Sp 1 levels (Abdelrahim 
et al. , 2006). Accordingly, this study was designed to examine the capability of 
tolfenamic acid to decrease the levels of the transcription factor Sp 1, and 
therefore, other AD involved proteins and peptides like APP and AB within 
animals' brains. Consequently, the drug was administered to C57BL/6 mice and 
Hartley guinea pigs. Different doses of the drug were tried to find the dosage 
range where efficacy is achieved. Animals also were sacrificed at different time 
points, in order to study the drug effects over the time course of the study. Data 
showed that tolfenamic acid was able to lower SP l, APP and AP in the brains of 
animal models in a time dependent manner, and within certain doses. These 
studies demonstrate that tolfenamic acid 1s a potential candidate for further 
development as a treatment for AD. 
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1.0 Introduction 
1.1 Background and significance 
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by 
dementia evolving till death. During the course of the disease, memory, cognitive 
performance, and other daily activities are all impaired . In 2000, the number of 
AD cases in the US was about 4.5 million (Hebert et al., 2003), this number has 
reached 5.2 million in 2008 (Alzheimer's Association, 2008), it was estimated it 
would grow up to 13.2 million in 2050 (Hebert et al., 2003). In addition, 
Brookmeyer et al. (2007) predicted that that the number of AD cases around the 
world grow from 26.6 million in 2006 to 106.8 million in 2050. Annual AD-
associated costs were estimated to be at least 100 billion dollars solely in the US 
(Fi llit, 2000). So far, no cure was found for AD, and all available medications are 
prescribed for symptomatic or adjuvant therapy. 
The characteristic neuropathological deposits identified in AD are the 
extracellular Amyloid beta (AP) plaques and intracellular tau tangles (Terry et al. , 
1964; Thal et al., 2004; Goedert and Spillantini, 2006). Alois Alzheimer described 
those neuritic plaques and neurofibrillary tangles more than a hundred years ago 
(Goedert and Spillantini , 2006). Since then, numerous studies have explored these 
plaques and tangles (Terry et al., 1964; Evin and Weidemann, 2002; Thal et al., 
2004; Goedert and Spillantini , 2006). Under the electron microscope, these 
deposits display abnormal filaments (Terry et al., 1964). A recent study confirmed 
these findings , as extensive AP depositions were found in the neocortex and 
caudate nuclei of AD patients, and these deposits were more abundant in AD than 
in healthy controls; dementia with Lewy bodies; frontotemporal dementia; and 
mild cognitive impairment (Rowe et al. , 2007). 
The main component of AD plaques is the AP peptide. It is 39-43 amino acids 
long, and is generated by cleavage of the amyloid precursor protein (APP) (Haass 
et al., 1991 ; Urbane et al., 1999). This amyloidogenic pathway involves cleavage 
of APP by the enzyme P-secretase, followed by y-secretase. The produced AP is 
normally secreted, but also can accumulate resulting in formation of insoluble 
aggregates (Shoji et al., 1992; Urbane et al. , 1999). Two forms of AP can be 
generated, AP4o and AP42, the difference between the two is not only in the 
number of amino acids in their composition, but also AP42 was found to be more 
aggregative, and it was proposed that AP42 triggers plaque formation in AD 
(Naslund et al., 2000). Furthermore, Shoji et al. (1992) suggest that formation of 
the insoluble AP depositions depends on the rate of AP production and the rate of 
its elimination. Accordingly, the amyloid hypothesis of AD was developed, 
suggesting that amyloid plaque aggregates formed by the amyloidogenic 
breakdown of APP cause the neurodegeneration and dementia seen in AD 
(Selkoe, 1993; Hardy and Selkoe, 2002). On the other hand, APP also can be 
processed by a non-amyloidogenic pathway, where it is cleaved within the AP 
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region, resulting in secreted products that do not form deposits (Shoji et al., 
1992). This occurs following APP cleavage by the enzyme a-secretase. 
The specificity protein 1 (Sp 1) is a transcription factor involved in the pathology 
of AD (Zawia and Basha, 2005; Basha et al., 2005; Santpere et al., 2006). Sp 1 
acts as a co-activator in the process of the transcription of APP (Docagne et al., 
2004). Previous studies have shown that the APP promoter includes several Sp 1 
binding sites (Lukiw et al., 1994; Hoffman and Chernak, 1995; Querfurth et al., 
1999; Zawia and Basha, 2005). Furthermore, Sp 1 greatly regulates the expression 
of beta site APP cleaving enzyme 1 (BACE 1) (Christensen et al., 2004). BACEI 
is the main form of P-secretase that cleaves APP to generate AP (Cai et al., 2001). 
Christensen et al. (2004) found that overexpression of SP 1 increases BACE 1 
promoter activity, while the decline in Sp 1 protein reduces transcription of the 
BACE 1 gene. Likewise, silencing the Sp 1 gene dramatically reduces APP 
promoter activity (Basha et al., 2005). In addition, in vivo immunohistochemical 
results have shown that Sp I, APP, and AP co-localize in brain neurons (Brock et 
al., 2008). In addition, Sp I regulates the expression of phosphorylated tau 
(Heicklen-Klein and Ginzburg, 2000). The buildup of hyper-phosphorylated tau 
results in the formation of the pathogenic tangles found in AD and some other 
neurodegenerative disorders like Pick's disease (Santpere et al ., 2006). 
Early-onset familial AD (FAD) compromises 5-10% of all AD cases. The 
majority of FAD is related to mutations on genes encoding the presenilin (PS) 
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membrane proteins, PS-1 , PS-2 (Czech et al., 2000). Presenilin mutations increase 
production of AP42 from APP, and increased AP42 levels were observed in the 
blood and brains of FAD patients with presenilin abnormalities (Czech et al., 
2000). In addition, neurons lacking the PS- I gene fail to produce AP peptides (De 
Strooper et al. , 1998; Naruse et al., 1998). Consequently, PS-I was found to be 
related to the activity of the enzyme y-secretase (De Strooper et al. , 1998; 
Shimojo et al. , 2007). AP and its aggregates also were found to cause synaptic 
dysfunction and loss (Mattson, 1997; Takahashi , 2002; Fein et al., 2008). 
Collectively, these findings confirm the involvement of AP in the pathology of 
AD. The role of Spl , APP and AP in plaque formation and AD is illustrated in 
Fig. I . 
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Figure 1. A proposed transcriptional pathway for brain amyloid plaque formation. 
Sp I binds to the promoter region of the APP gene, resulting in enhancement of 
APP transcription and tarnslation. APP is then cleaved first by the enzyme P-
secretase, and then by y-secretase to produce Ap, which can aggregate forming 
the amyloid plaques that contribute to the pathology of AD. 
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To date, no drug has been found to stop the progression of AD. All available 
medications are prescribed as symptomatic or adjuvant therapy. FDA approved 
drugs for AD include acetylcholinesterase inhibitors and the N-methyl-D-
aspatarte (NMDA) receptor antagonist memantine. The rational for using 
cholinesterase inhibitors in AD is based on the cholinergic hypothesis, in which 
the decline in cholinergic function with age was proposed to contribute to the 
cognitive dysfunction in AD (Bartus et al., 1982). Accordingly, cholinesterase 
inhibitors like donepezil, rivastigmine, and galantamine are currently prescribed 
for mild to moderate AD, and have produced improvement in disease symptoms 
(Francis et al., 1999). The other drug approved for treating AD is memantine, an 
NMDA receptor antagonist that blocks the excitotoxicity effects of glutamine, and 
is used in moderate to severe cases of AD (Reisberg et al., 2003). Improved AD 
symptoms were observed with memantine administration (Mobius . and StOffler, 
2003; Reisberg et al., 2003). Additionally, antipsychotics and antidepressants are 
sometimes prescribed to manage corresponding ailments that can arise in AD 
patients (Lesser and Hughes, 2006). Non-prescription medications also are used 
for their anti-oxidant properties like the vitamins C and E, however, their use in 
AD is controversial (Boothby and Doering, 2005). 
Considering the large and increasing number of AD cases and the devastating 
course of the disease, there is a great need for developing drugs that target critical 
pathologic mechanisms in AD. Continuing research revealing additional insights 
into the pathogenesis and molecular mechanisms behind AD has created more 
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hope for disease modifying therapies, rather than merely symptomatic treatment. 
New mechanisms are under investigation for the design of new drugs for AD. 
Many approaches targeting the pathological plaques of AD are being examined, 
particularly those exploring different factors in the production, secretion, and 
degradation of AP peptides (Roberson and Mucke, 2006). 
Epidemiological studies have demonstrated that chronic exposure to non-steroidal 
anti-inflammatory drugs (NSAIDs) has a positive effect on AD. NSAIDs exert 
their anti -inflammatory effects by blocking the cyclooxygenase (COX) mediated 
production of prostaglandins. Various mechanisms have been suggested for 
NSAIDs' role in AD. According to a meta-analysis of different studies on 
NSAIDs in AD, it was found that NSAIDs exposure reduced the risk for AD 
development (Szekely et al., 2004). However, these effects were not consistent 
among all NSAIDs, and in all studies. It was proposed that NSAIDs decrease 
BACE I levels as they activate the peroxisome proliferator-activated receptor-y 
(PPARy) and that would be how they exert their protective effect in AD (Sastre et 
al., 2006). Other studies suggested that NSAIDs act by affecting y-secretase 
activity, resulting in the decrease of AP42 production, apart from their COX 
inhibition activity (Weggen et al., 2001; Eriksen et al., 2003). 
Tolfenamic acid is an NSAID currently used to treat migraine symptoms m 
humans in Europe, and for pain management in veterinary medicine in the US. 
Recently, tolfenamic acid also was found to decrease the levels of transcription 
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factors Sp 1, Sp3, and Sp4 in pancreatic tumors, and thus inhibit their growth 
(Abdelrahim et al., 2006). Since Sp 1 is associated with the pathology of AD 
(Basha et al., 2005; Santpere et al., 2006), particularly through APP transcription 
coactivation (Docagne et al., 2004), and regulating BACE 1 expression 
(Christensen et al., 2004), this study was designed to examine the potential of 
tolfenamic acid as a new therapeutic intervention for AD. 
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1.2 Objectives 
Previous studies from our lab have shown that the transcription factor Spl is 
associated with the pathology of AD. Increased APP mRNA expression later in 
life following prior lead exposure early in life was coupled with increased Sp I 
activity (Basha et al., 2005, Wu et al. 2008). Furthermore, recently published in 
vivo immunohistochemical results have confirmed the formerly established link 
between Sp I and APP, and have proposed that AP is more likely to be found in 
cerebral cortex and hippocampal areas with higher Sp I levels (Brock et al., 2008). 
This study was designed to examine Sp I as a target involved in a possible 
therapeutic intervention of Alzheimer's disease. Tolfenamic acid is an NSAID 
found to lower Sp I levels, and subsequently inhibit the growth and angiogenesis 
of pancreatic tumors (Abdelrahim et al, 2006). Accordingly, this research work 
was conducted to investigate the ability of tolfenamic acid to lower AD associated 
proteins like APP and AP through its action on Spl, as illustrated in Fig. 2. 
Specific aims 
1. Examine the ability of tolfenamic acid to reduce APP and AP protein levels in 
the brains of wild type animal models exposed to the drug. 
2. Test the ability of tolfenamic acid to decrease levels of the transcription factor 
Sp I within the brains of animal models dosed with tolfenamic acid. 
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Figure 2. Proposed down-regulation of the APP gene by tolfenamic acid. 
Tolfenamic acid promotes the degradation of the transcription factor Sp 1. Sp l 
decline results in a decrease in APP transcription, and thus lowers APP and AP 
levels. This would be expected to diminish amyloid plaque pathology. 
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1.3 Experimental design 
C57BL/6 mice were exposed to different doses of tolfenamic acid or vehicle in 
order to examine whether the drug can affect the fol lowing proteins: APP, SP 1, 
and AP in comparison to vehicle. At first, a pilot study was conducted using a few 
doses of tolfenamic acid in a small number of animals. The study was repeated 
with a wide but safe selection of doses of tolfenamic acid, in order to examine the 
dose range where the drug was affecting AD related proteins. Moreover, animals 
were sacrificed at different time points during the study, in order to examine the 
changes in those proteins over time. In addition, tolfenamic acid also was tested in 
Hartley guinea pigs, as they have been suggested to represent a better animal 
model for studying pathological changes related to AD, since their AP peptides 
are identical to the ones found in humans (Beck et al. , 2003). Following each 
study, the brains of these animals were tested for changes in the levels of their 
APP, SP 1, and AP peptides by the proper analytical techniques. 
13 
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2.0 Materials and methods 
Materials and instruments 
Most chemicals and reagents were purchased form Thermo Fisher Scientific Inc. 
(Rockford, IL) unless otherwise noted. Tolfenamic acid was purchased from LKT 
Laboratories Inc. (St. Paul , MN). Micro BCA Protein Assay Kit and Super signal 
Ultra from Pierce (Rockford, IL). Nitrocellulose transfer membranes from Bio-
Rad Laboratories (Hercules, CA). PVDF transfer membranes from GE Osmonics 
Labstore (Minnetonka, Mn). ECL Plus Western Blotting Detection Reagents, 
ImageQuant™ 5.2 software, and the Typhoon™ Variable Mode Imager from GE 
Healthcare Bio-Sciences Corporation. (Piscataway, NJ). KODAK Image Station 
2000MM from Eastman Kodak (Wood Dale, IL). Primary antibodies against 
APP, actin, and GAPDH were from Sigma Chemical Co. (St. Louis, MO). 
Additionally, APP primary antibody was purchased from Millipore Corporation. 
(B illerica, MA). SPI antibody was obtained from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA). Human AP (1-40) and (1-42) ELISA assay kits were from 
Immuno-Biological Laboratories (Gunma, Japan) . 
Animal Exposure 
Mice (C57BL/6 strain) were either bred in-house or obtained from Charles River 
Laboratories (Shrewsbury, MA) or Jackson Laboratory (Bar Harbor, ME). Guinea 
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pigs (Hartley strain) were purchased from Charles River Laboratories 
(Shrewsbury, MA). Animals were housed in rooms designated for each species 
within the animal facility at URI. 
Mice of the C57BL/6 strain were used as they have already been employed for 
AD research. Guinea pig A~ is identical to that of humans (Beck et al., 2003; 
Anderson et al.,2005; Du et al., 2007), and like humans, guinea pigs were found 
to be one of the animal models that express neuritic plaques in vivo, while 
plaques can not be found in smaller animals like mice and rats (Beck et al., 2003). 
However, no plaques were seen within the brains of 10 guinea pigs with ages up 
to 10 years old (Rossner, personal communication, December 22, 2007). The fact 
that these animals express structures similar to neutritic plaques found in human 
brains was first cited in a German source that dates back to 1910, nevertheless, 
this book did not provide any images of those plaques (Previous source; Beck et 
al., 1997). Since then, numerous articles have mentioned that plaques are 
naturally present within the guinea pig brain, while a thorough literature review 
revealed no further information or images supporting such statements. 
Animals were exposed to tolfenamic acid prepared in corn oil through gavage 
(oral dose) for 4-5 weeks. Animals were divided into groups of 2-6 animals in 
each, including a control group receiving corn oil; and experimental groups 
receiving either 1, 5, I 0, 25, 50, or 150 mg/kg body weight doses of tolfenamic 
acid in corn oil. Cremophor was used as the solvent for the tolfenamic acid 
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fo rmulation administered to guinea pigs, since the 50 mg/kg dose could not be 
ach ieved in a small volume of corn oil , as the animals were I 0 times the weight of 
mice. The standard guidelines and the protocol approved by IACUC were 
fo ll owed for animal handling. Animals were euthanized by C02 asphyxiation in a 
specially designed canister for that purpose. They were left in the canister to be 
rendered unconscious and dead. The dead animals also were decapitated to 
eliminate any uncertainty. This method is consistent with the recommendations of 
the Panel on Euthanasia of the American Veterinary Association. The brains of 
these animals were isolated, and the various regions; cerebral cortex, 
hippocampus, cerebellum and brain stem; were separated on dry ice and stored at 
-80°C. The effect of tolfenamic acid on APP and AP peptides was examined 
within the cerebral cortices of brain samples. 
Accordingly, and due to study requirements, four separate and independent 
animal experiments were conducted. First, a small number of 2 months old male 
C57BL/6 mice were dosed every other day (i .e. 3 times a week), with either corn 
oil, I 0, 50, or 150 mg/kg tolfenamic acid in corn oil for 5 weeks. Ln the following 
study, l month old male Hartley guinea pigs were dosed every other day with 50 
mg/kg tol fenamic acid solution in cremophor or vehicle for 4 weeks. The third 
experiment conducted included dosing of female C57BL/6 mice with either 5, 10, 
or 25, mg/kg tolfenamic acid in corn oil, or vehicle every other day for four 
weeks. And finally tolfenamic acid was administered daily to male C57BL/6 mice 
in one of the following doses 0 (vehicle) 1, 5, 10, 25, or 50 mg/kg. All tolfenamic 
16 
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acid formulations for the first three studies were kindly provided by Dr. Maen 
Abdelrahim (Anderson Cancer Center, Orlando Cancer Research Institute, 
Orlando, FL). Guinea pig brains were kindly donated by Dr. Thomas Mather 
(Un iversity of Rhode Island, Kingston, RI), to conduct Western blot analyses and 
ELISA assays necessary for early optimization of experimental conditions. 
Female C57BL/6 mice were kindly given by Dr. Angela Slitt (University of 
Rhode Island, Kingston, RI). 
Protein extraction 
Approximately 0.1 gm of cerebral cortex tissue was homogenized with 500 µI of 
the RIPA lysis buffer (10 mM Tris-HCI [pH 7.4], 150 mM NaCl, 1% Triton X-
100, 0.1 SOS, 1 mM EDTA). The homogenate was then centrifuged at 10,000 
rpm for I 0 minutes at 4°C, and the supernatant was collected. Protein 
concentration was determined using the Micro BCA Protein Assay Kit. Extracts 
were stored at -80°C until used. 
Western Blot Analysis 
Western blot analysis was performed to observe the changes in the levels of SP 1, 
APP, and the housekeeping proteins actin and GAPDH among control and 
treatment tissues. The method mentioned in previous studies was followed 
(Atwood et al., 1998; Nunomura et al., 1999; Atkins et al., 2003). In brief, 
17 
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samples were loaded onto 8% gels (5.35 H20, 2.5 ml of 1.5 M Tris-HCI, [pH 8.8], 
100 µI of 10% SDS, 2 ml of 40% Acrylamide/Bis, 50 µI of 10% Amonium 
Persulfate, and 5 µI TEMED). The samples were then run for about 1-2 hours at 
20-30 mA, transferred to nitrocellulose or PVDF membranes, fixed, and blocked 
with 5% non-fat milk overnight. After that, the membranes were incubated with 
the specific primary antibody for 1-2 hours at room temperature, then with the 
secondary antibody for 1 hour at room temperature, and finally with ECL plus 
reagent for 1 minute. The florescence of Western blot bands was detected using 
the Typhoon™ Variable Mode Imager. In some experiments, Super signal Ultra 
was used to detect chemilumescence where the membranes were incubated with 
the substrate for 3-5 minutes and the signal was detected using the KODAK 
Image Station 2000MM. Quantitative assay of the bands was performed using 
ImageQuant™ 5.2 software. 
ELISA A~ (1-40) and AP (1-42) Assay 
The levels of AP were measured using human AP ( 1-40) and ( 1-42) assay kits. 
These kits are solid-phase sandwich ELISA with two kinds of highly specific 
antibodies, which are I 00% cross reactive with mouse AP (1-40), and 70% cross 
reactive with mouse AP (1-42). The assay was conducted as mentioned within the 
manufacturer's instructions (Immuno-Biological Laboratories, Gunma, Japan) and 
Morishima-Kawashima et al. (2000) with minor modifications. I 00 µg of protein 
samples in 100 µI of EIA buffer and assay standards were added to a 96-well 
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plates pre-coated with anti-human AP mouse IgG MoAb. The plates were 
incubated overnight at 4°C. Plates were washed using the 40X diluted wash buffer 
supplied with the kit (0.05% Tween20 in phosphate buffer) for 7 times, 
afterwards, 100 µL of labeled antibody were added to the samples and standards, 
and they were incubated for one hour at 4°C. The plates were washed again 9 
times, and then 100 µL of tetramethylbenzidine were added as a coloring agent. 
The plates were incubated in the dark for 30 minutes at room temperature. Finally 
100 µL of 1 N H2S04 were added to stop the reaction, and absorbance was 
measured at 450 nm using a UV/Vis Spectrometer. The concentration of AP in 
unknown samples was obtained as pg per mg protein after plotting the absorbance 
of standards against the standard concentrations. 
Statistical Analysis 
Data were represented as the mean ± the standard error of the mean (SEM). 
Statistical analysis was performed using two-tailed Student's I-test, and results 
marked with an asterisk were significantly different from the control group 
(p<0.05). 
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3.0 Results 
The transcription factor Sp I is an essential factor within the pathology of AD 
(Christensen et al., 2004, Basha et al. , 2005, Santpere et al. , 2006). Tolfenamic 
acid was found to stimulate the degradation of Sp 1 in pancreatic tumor cells 
(Abdelrahim et al., 2006). Accordingly, the effects of tolfenamic acid 
administration on proteins related to AD pathology were examined in animal 
models. Four studies were conducted to observe changes in APP and A~ levels, 
protei ns that are affiliated with the neurodegeneration in AD according to the 
amyloid hypothesis. Within these studies, different doses of tolfenamic acid were 
tested and compared to the vehicle controls. The dose range effects were 
examined in samples obtained from the animals ' cerebral cortexes. 
3.1 A pilot study in male C57BL/6 mice 
Treatment with 10 and 50 mg/kg of tolfenamic acid every other day for five 
weeks significantly reduced APP protein levels in the cerebral cortex of male 
mice when compared to controls (student's t test p <0.05) (Fig. 3A). SP I protein 
leve ls were lower in I 0 mg/kg treated animals as demonstrated by Western blot 
analys is (Fig.3B). A~ ( 1-40) protein levels also were significantly reduced within 
the cerebral cortex of the same treatment groups in comparison to controls 
(student ' s t test p <0.05) (Fig. 4). 
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Figure 3. APP and SP! levels in mice treated with tolfenamic acid. Animals were 
two months of age at the beginning of the study. They were given 0, l 0, or 50 
mg/kg tolfenamic acid (n=3 in each dose group). Doses were administered three 
times a week for 5 weeks by oral gavage. (A) APP levels in cerebral cortex 
samples from control and tolfenamic acid treated animals. APP protein levels 
were expressed as a ratio of the housekeeping protein GAPDH as measured by 
Western blot analysis, described in the methods section. Values are shown as the 
mean ± SEM. Results for treatment animals (n=6) were pooled together as their 
values compared to each other were not statistically significant. The"*" indicates 
that values are significantly different from control, as determined by a student's t-
test (p<0.05). (B) SPl Western blot results of samples from mouse brain extracts 
from controls and animals treated every other day with 10 mg/kg tolfenamic acid 
for 5 weeks. 
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Figure 4. AP (1-40) levels in male mice treated with tolfenamic acid. Animals I 
were two months of age at the beginning of the study. They were given vehicle, 
10, or 50 mg/kg tolfenamic acid (n=3 in each dose group). Doses were 
administered three times a week for 5 weeks by oral gavage. AP levels were 
measured in pg/mg protein using an ELISA assay as described in the methods 
section. Values shown are the mean ± SEM. Results for treatment animals (n=6) 
were pooled together as their values compared to each other were not statistically 
significant. The " *" indicates that values are significantly different from control, 
as determined by a student' s t-test (p<0.05). 
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3.2 A pilot study in male Hartley guinea pigs 
In guinea pigs 50 mg/kg tolfenamic acid in cremophor decreased APP cerebral 
cortex levels by thirty percent in comparison to controls as determined by 
Western blot analysis, following 4 weeks of every other day dosing (n=3). This 
change was significant (p=0.01) according to student's I-test (Fig. 5). A~ (l-42) 
displayed a lowering trend, but it was not statistically significant according to 
student's I-test (p= 0.23) (Fig. 6). 
3.3 A study in female mice 
After tolfenamic acid was administered to female mice, three times a week, for 
four weeks, cerebral cortex APP levels were significantly lowered with l 0 and 25 
mg/kg doses by 52.18% and 40.58% respectively (student's I-test p<0.05). APP 
also was lower within the cerebral cortex samples obtained from animals dosed 
with 5 mg/kg, however, this change was not statistically significant as determined 
by student's I-test (p=0.11) (Fig. 7). 
On days 4 and 8, the APP/GAPDH ratio was not changed. However, on day 16 
there was a clear downward trend (23%). By day 29, 10 mg/kg tolfenamic acid 
decreased APP levels by 52.18% as a percentage change from control, which was 
statistically significant, student's I test p =0.0 I (Fig. 8). 
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Figure 5. Changes in APP levels in guinea pigs treated with tolfenamic acid. 
Animals' age was one month at the beginning of the study. They were given 
either vehicle or 50 mg/kg tolfenamic acid orally three times a week for 4 weeks . 
APP protein levels in cerebral cortex samples were expressed as a ratio of the 
housekeeping protein GAPDH as measured by Western blot analysis described in 
the methods section. Values shown are the mean± SEM (n=3). The "*" indicates 
that the change is statistically significant, as determined by student's t-test 
(p=0.01). 
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Figure 6. A~ (1-42) levels in guinea pigs exposed to tolfenamic acid. Animals 
were two months old at the beginning of the study. They were dosed with either 
vehicle or 50 mg/kg tolfenamic acid orally three times a week for 4 weeks. A~ (I-
42) levels in cerebral cortex protein samples were measured as pg/mg protein by 
an ELISA assay as described in the methods section. Values shown are the mean 
± SEM (n=4). 
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Figure 7. APP levels in the cerebral cortex of female mice treated with various 
doses of tolfenamic acid. Animals' age was two-three months at the beginning of 
the study. Vehicle, 5, 10, or 25 mg/kg tolfenamic acid were administered three 
times a week by oral gavage for four weeks. APP protein levels in cerebral cortex 
samples were expressed as the ratio of the housekeeping protein GAPDH, as 
measured by Western blot analysis described in the methods section. Values 
shown are the mean ± SEM. The number of animals in each group was: control 
(n=2); 5 mg/kg (n=3); 10 mg/kg (n=5); and 25 mg/kg (n=2). The "*" indicates 
that values are significantly different from control, as determined by a student's!-
test (p<0.05) . 
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Figure 8. Temporal changes in APP levels in cerebral cortex of female mice 
treated with tolfenamic acid. Animals ' age was two months at the beginning of 
the study. They were given either vehicle or 10 mg/kg tolfenamic acid three times 
a week by oral gavage. Control and treatment animals were sacrificed on day 4, 8, 
and 29 after the beginning of the study. Results are expressed as the percentage of 
APP/GAPDH change from each group ' s control as obtained by Western blot 
analys is described in the methods section. The number of animals in each group: 
day 4 control (n=2), treatment (n=4); day 8 control (n=2), treatment (n=4); day 29 
control (n=2), treatment (n=5) . The "*" indicates that values are significantly 
different from control, as determined by a student ' s t-test (p<0.05). 
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3.4 A time and dose range finding study 
To determine the range of effective doses, tolfenamic acid was administered daily 
at the following concentrations: 1, 5, l 0, 25, and 50 mg/kg. It was observed that 
cerebral cortex APP levels were significantly lowered (student's t-test p=0.04) by 
18.52% with the 5 mg/kg dose. The remaining four doses resulted in no change 
(Fig. 9). 
Moreover, changes in APP with the 5 mg/kg treatment were examined at different 
time points. On days 4 and 8, there were non-significant fluctuations in APP 
levels. However, there was as a nearly significant 20% lowering trend (p=0.13) of 
APP levels 8 days following daily tolfenamic acid administration. On day 16, 
tolfenamic acid significantly decreased APP levels by 18.52%, student's t test 
p=0.04 (Fig. 10). 
Changes in SPJ levels also varied in response to different doses of tolfenamic 
acid (Fig. 11 ). SP I protein was significantly less than control in the cerebral 
cortex of animals treated daily with 5 and l 0 mg/kg tolfenamic acid, with the 
percentages of change from control being 57 .65%, and 30.13% respectively 
(Student's t-test p=0.02, p=0.05). 
Changes in levels of AP (1-40) at day 16 following daily doses of 1, 5, 25 , 50 
mg/kg tolfenamic acid compared to controls are shown in Fig. 12. Treatment 
I 
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animals' AP ( 1-40) was lower than controls by the following percentages; 24.32% 
with the 1 mg/kg dose (p=O .O 1); 14.27% with 5 mg/kg (p=0.06); 25.29% with 25 
mg/kg (p=0.02); and 21.61 % with 50 mg/kg (p=0.05). AP (1-42) changes can be 
examined from Fig. 13, AP ( 1-42) levels were significantly lower than controls by 
the following percentages; 32.81 % with the 1 mg/kg dose (p=0.05) 68 .2% with 5 
mg/kg (p=0.02); 32.96% with 25 mg/kg (p=0.02); and 29.45% with 50 mg/kg 
(p=0.0004). 
The overall changes in SP 1, APP, and AP following daily dosing with different 
doses of tolfenamic acid for 15 days are summarized in Table 1. Accordingly, 
higher doses of tolfenamic acid and a dose as low as 1 mg/kg administered daily 
did not alter SPl (Fig. 11), but still had a lowering effect on AP (Fig. 12, Fig. 13). 
The changes occurring in AP (1-40) during the time course of the 5 mg/kg daily 
treatment are demonstrated in Fig. 14. Only on day 16 post treatment, AP ( 1-40) 
levels dropped by 14.06% (p=0.06). The changes in AP (1-42) were examined 
following daily 5 mg/kg administration of tolfenamic acid for 15 days (Fig. 15). 
Exclusively on day 16 a statistically significant change could be observed with -
68.2% percentage change in AP (1-42) (p=0.02). 
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Figure 9. APP levels in the cerebral cortex of mice treated with various doses of 
tolfenamic acid. Animals' age was 3 months at the beginning of the study. 
Animals were dosed with 0, 1, 5, I 0, 25, or 50 mg/kg tolfenamic acid by oral 
gavage daily for 15 days. APP levels detected by Western blot are shown as a 
ratio of the levels of the housekeeping protein actin. Values shown are the mean± 
SEM. The number of animals in each group: control n=2; 1 mg/kg n=3; 5 mg/kg 
n=3; 10 mg/kg n=4; 25 mg/kg n=4; 50 mg/kg n=3. The"*" indicates that values 
are significantly different from controls, as determined by a student's t-test 
(p<0.05). 
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Figure I 0. Temporal changes in APP levels in the cerebral cortex of mice treated 
with tolfenamic acid. Animals ' age was 3 months at the beginning of the study. 
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Vehicle or 5 mg/kg tolfenamic acid were administered daily, and animals were 
sacrificed at days 4, 8, and 16 following commencement of the treatment. Results 
are expressed as the percentage of APP/actin change from each group ' s controls 
as obtained by the Western blot analysis described in the methods section. The 
number of animals in each group, day 4 control n=4, treatment n=S; day 8 control 
n=3, treatment n=3 ; day 16 control n=2, treatment n=3. The "*" indicates that 
values are significantly different from control , as determined by a student ' s t-test 
(p<0. 05). 
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Figure 11. SP I levels in the cerebral cortex of mice treated with different doses of 
tolfenamic acid. Animals ' age was 3 months at the beginning of the study. They 
were treated with 0, I , 5, 10, 25, or 50 mg/kg tolfenamic acid daily by oral gavage 
for 15 days. SP I protein levels were expressed as a ratio of the housekeeping 
protein actin measured by Western blot analysis, described in the methods 
section. Values shown are the mean ± SEM. The number of animals in each 
group : control n=2; 1 mg/kg n=4; 5 mg/kg n=3; 10 mg/kg n=4; 25 mg/kg n=5 ; 50 
mg/kg n=5. The "*" indicates that values are significantly different from control , 
as determined by a student' s t-test (p<0.05). 
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Figure 12. AP (1-40) levels in the cerebral cortex of mice treated with various 
doses of tolfenamic acid. Animals were 3 months at the beginning of the study. 
They were given one of the following doses of tolfenamic acid 0, 1, 5, 25, 50 
mg/kg. The drug was administered daily by oral gavage for 15 days. AP (1-40) 
levels were measured by an ELISA assay according to the procedures illustrated 
in the methods section. Results shown are the mean ± SEM. The number of 
animals in each group, control n=3; lmg/kg n=4; 5 mg/kg n=4; 25 mg/kg n=5; 
and 50 mg/kg n=4. The "*" indicates that values are significantly different from 
control, as determined by a student's t-test (p<0.05). 
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Figure 13. AP ( 1-42) levels in the cerebral cortex of mice treated with various 
doses of tolfenamic acid. Animals were 3 months at the beginning of the study. 
They were given one of the following doses of tolfenamic acid 0, 1, 5, 25, 50 
mg/kg. The drug was administered daily by oral gavage for 15 days. AP (1-42) 
levels were measured by an ELISA assay according to the procedures illustrated 
in the methods section. Values shown are the mean ± SEM. The number of 
animals in each group: control n=3; I mg/kg n=4; 5 mg/kg n=3; 25 mg/kg n=4; 
and 50 mg/kg n=5. The "*" indicates that values are significantly different from 
control, as determined by a student's t-test (p<0.05). 
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Table 1. A Summary of the effect of daily dosing with various doses of 
tolfenamic acid on SP I, APP and A~. Animals' age was 3 months at the 
beginning of the study. Animals were given one of the following doses of 
tolfenamic acid 0, I, 5, 25, or 50 mg/kg, daily for I 5 days. Protein changes are 
expressed as percentage change from controls. 
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Dose SPl 
_im_g_/kg) 
1 No 
chan__g_e 
5 -57.65% 
25 No 
chan__g_e 
50 No 
chan__g_e 
APP 
No change 
-18.52% 
No change 
No change 
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AP (1-40) 
-24.32% 
-14.27% 
-25.29% 
-21.61 % 
AP (1-42) 
-32.81% 
-68.19% 
-32.96% 
-29.54% 
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Figure 14. Temporal changes in AP (l-40) levels in the cerebral cortex of mice 
treated with tolfenamic acid. Animals' were 3 months of age at the beginning of 
the study. Vehicle or 5 mg/kg tolfenamic acid were administered daily, and 
animals were sacrificed at days 4, 8, and 16 after the beginning of the study. AP 
( l-40) levels were measured by an ELISA assay as illustrated in the methods 
Ii section. Results expressed are the mean ± SEM. The number of animals in each 
group, day 4 control n=4, treatment n=5 ; day 8 control n=4, treatment n=5; day 16 
control n=3, treatment n=4. (p=0.06) according to student ' s t-test, at day 16. 
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Figure 15. Temporal changes in AP (1-42) levels in the cerebral cortex of mice 
treated with tolfenamic acid. Animals' were 3 months at the beginning of the 
study. Vehicle or 5 mg/kg tolfenamic acid were administered daily, and animals 
I 
were sacrificed at days 4, 8, and 16 after the beginning of the study. AP (l-42) ii 
levels were measured using an ELISA assay as illustrated in the methods section. 
Values shown are the mean± SEM. The number of animals in each group, day 4 
control n=4, treatment n=5; day 8 control n=4, treatment n=5; day 16 control n=3, 
treatment n=3. The "*" indicates that values are significantly different from 
control, as determined by a student's t-test (p<0.05). 
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4.0 Discussion 
Alzheimer' s disease is a neurodegenerative disorder causing progressive memory 
depreciation until death. While the exact cause remains unknown, no disease 
modi fy ing drug is available, and all existing medications only target the 
symptoms. The presence of AP plaques and tau neurofibrillary tangles within the 
cerebral cortex and hippocampal regions of the brain are the two major known 
characteristics of the disease. AP is the product of the sequential cleavage of APP 
by the enzymes P-secretase and y-secretase. Since the amyloid hypothesis has 
closely linked these proteins with the pathology of AD (Hardy and Selkoe, 2002), 
AP and other elements involved in its production have been targets for possible 
therapeutic interventions. 
The transcription factor Sp I has been linked to the pathology of AD. It is 
invo lved in regulating the APP gene as well as BACE l (Christensen et al. , 2004; 
Docagne et al., 2004; Basha et al. , 2005 ; Santpere et al., 2006). Therefore, any 
process that impacts Sp l is likely to have an effect on APP levels as well as its 
downstream products. Tolfenamic acid was shown to inhibit pancreatic tumors 
growth by promoting the degradation of the transcription factors Sp 1, Sp3, and 
Sp4, and suppressing VEGF mRNA and protein expression (Abdelrahim et al. , 
2006). Thus, tolfenamic acid is likely to lower APP levels in the brain. 
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In our studies, tolfenamic acid demonstrated a time dependent effect on APP and 
A~ levels within certain doses; these are major pathological mediators in AD 
according to the amyloid hypothesis. These effects were accompanied by a 
correlated drop in the levels of the transcription factor SP 1 at certain doses. Those 
results were first observed in a pilot trial in male mice where APP levels were 
lowered by about 50% (Fig. 3A), and A~ levels by 18% (Fig. 4). SPl protein 
bands also were of lower intensity in the treated group than the control (Fig. 3B). 
APP levels also were lower in male guinea pigs following tolfenamic acid 
treatment (Fig. 5); however, the reduction in APP was less than that seen in mice. 
Furthermore, A~ (1-42) levels were mitigated but not significantly (Fig. 6). This 
is more likely due to the small sample number used in this study. The findings in 
guinea pigs demonstrate that the effects of tolfenamic acid on APP are not 
species-specific. 
In female mice, the same reduction levels were achieved after 28 days of alternate 
day dosing (Fig. 7). This indicated that the effects of tolfenamic acid are not 
gender-specific and appear to follow the same dose and time course requirements. 
The relationship between AD and gender has been disputed as some studies 
concluded that AD is indifferent to gender, while others argued that there was a 
higher risk in women for developing AD (Barnes et. al., 2005). Our studies show 
that tolfenamic acid had a similar effect on APP in male and female C57BL/6 
mice. 
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While alternate day dosing was selected in pilot trials to identify the time and 
dose ranges where tolfenamic acid effects can be observed, a more accurate 
determination can be achieved by daily dosing. Daily administration of tolfenamic 
acid resulted in a reduction in all three endpoints namely APP, SP 1, and AP at 
certain doses within 16 days (Table 1). The daily dosing time course was 
consistent with previous alternate day dosing as the time was cut in half in daily 
dosing. 
The delay in the observed reduction of APP and AP levels in animals strongly 
suggests that the lowering of these AD-related proteins is achieved through 
interruption of processes associated with gene expression and regulation (Fig 8, 
10, 14, 15). In pancreatic tumors, Spl inhibition was masked following treatment 
with proteasome inhibitor, proposing that tolfenamic acid degradation of Sp 1 is 
mediated by a proteasome (Abdelrahim et al., 2006). Such degradation would 
deplete a cell from SP 1 reserves, and over time, less APP expression would be 
expected due to a decreased pool of SPl. Likewise, the fact that AP levels take 
weeks to exhibit a decline, suggests that the lowering of this peptide is linked to 
the proteolytic elimination of SP 1 and lowered transcriptional activation of APP. 
Although the temporal condition of lowering these intermediates was relative to 
the dosing schedule, the effective dose range was very different. While higher 
doses of 10, 25 mg had an effect on alternate day dosing, the effects of daily 
dosing were only seen at 5 mg for APP and 5-10 mg for SP1. It is not clear why 
54 
the dose range was narrowed following daily dosing, but this maybe related to the 
half-life of the drug. In daily dosing a residual amount of the drug appears to 
persist that saturates the system and renders higher doses ineffective, while in 
alternate day dosing, the drug maybe washed out of the system before the next 
dose is administered. In any event, the lower sensitivity is greatly advantageous 
from a therapeutic perspective. 
The expression of the APP gene is regulated by Sp I (Basha et al., 2005). In the 
daily dosing study, it appeared that a 50% reduction in SP 1 levels had to be 
achieved before any lowering of APP could be detected. This suggests that the 
pools of SPl have to be reduced in half through tolfenamic acid induced 
degradation at a rate that overwhelms SPl synthesis. Tolfenamic acid thus acts to 
disrupt the balance between the de novo synthesis of APP and its degradation. 
While a narrowing of the dose range was observed relative to SPl and APP, AP 
levels on the other hand were lowered at daily doses tested from 1-50 mg/kg (Fig. 
12, 13). While both AP (1-40) and (1-42) were lowered, there was a greater 
lowering of AP (1-42) at the 5 mg dose. This is the dose where parallel reductions 
were seen in both SPl and APP. This leads to the conclusion that the effects on 
AP at the dose range of 1-10 mg is related to SPl and APP, while the lowering of 
AP at higher dose may be associated with other mechanisms. 
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The lowering of AP (1-42) is highly relevant because the 42 amino acid-long AP 
is considered more aggressive than the other forms, and resulted in more rapid 
aggregations in solutions with AP of varying sequences (Snyder et al., 1994; 
Naslund et al., 2000). In solution, AP (1-40) aggregates were found to inhibit the 
aggregation of AP (1-42) (Snyder et al. , 1994). The greater AP (1-42) decline 
compared to AP (1-40) following the 5 mg/kg dose of tolfenamic acid suggests 
that in vivo AP production might be shifted more towards the AP (1-40) fragment. 
It is not clear why at higher doses the drug did not affect Sp 1 and APP while AP 
was still lowered. A possible explanation could be that at higher doses the drug 
was aggregating, and thus was trapped in tissue before it could get into the brain 
in a concentration sufficient to cause Sp 1 and APP decline, in that case, cerebral 
cortex AP lowering could be explained by the tolfenamic acid triggered peripheral 
decline in AP acting as an AP sink from central compartments. This can be tested 
by studying the effects of the drug on Sp 1, APP, and AP in peripheral tissue. 
The pharmacokinetics of the drug could also play a role in the narrowing of the 
dosage range where effects are observed on Sp 1, APP and Ap. The elimination 
half-life of the drug from plasma was about 2.5 hours with 60 % bioavailability 
and 99.7% protein binding (Pentikainen et al., I 981; Sidhu et al. , 2006). However, 
the terminal clearance half-life of tolfenamic acid metabolites was as long as 19 
hours (Pentikainen et al. , 1984). Unpublished studies from our lab have confirmed 
that tolfenamic acid is available in the brain following oral or intramuscular 
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administration, still it is not yet proven whether the effects observed on Sp 1, APP, 
and AP are due to the parent compound or one of its metabolites. Nevertheless, 
one would expect the metabolites to be more polar and larger in size, and thus 
with lesser brain penetration potential than the parent drug; however, it is possible 
that some derivative of tofenamic acid is responsible for these effects. 
Furthermore, considering the fact that the rate and the degree of tolfenamic acid 
absorption and elimination are not dose dependent (Pentikainen et al. , 1981 ), 
higher doses of tolfenamic acid administered daily could have resulted in the 
depletion of the target proteasome that degrades Sp 1, and thus at such doses of 
tolfenamic acid, the target could have been used up, this would affect the response 
at the pharmacodynamic level. On the other hand, every other day administration 
might have allowed more time during which the body is drug free and the targets 
can be regenerated to be available for the next dosage. Nevertheless, doses as low 
as 5 mg/kg would still be more favorable, since they would be associated with 
fewer NSAID's related gastrointestinal side effects, and they are close to the doses 
approved for migraine headaches in humans, and pain control in veterinary 
medicine . 
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5.0 Conclusion 
These studies were primarily conducted to examine whether or not tolfenamic 
acid is capable of altering AP and APP protein levels, as important pathological 
intermediates in neurodegeneration and AD. Additionally, the studies aimed at 
finding the effective dose and time range at which such outcomes occur. 
Tolfenamic acid was able to lower the levels of cerebral SP I, APP, and AP with 
certain doses in wild type male mice. Temporal studies showed that the decline in 
APP and AP was time dependent. These effects seemed to be mediated through 
SP 1 degradation at a lower dose of the drug, i.e. 5 mg/kg administered daily. At 
higher doses AP lowering does not appear to be associated with the decrease in 
SPl decrease suggesting that there is an alternate mechanism underlying the AP 
change. In addition, tolfenamic acid lowered APP in the cerebral cortex of female 
mice, and Hartley guinea pigs. Accordingly, tolfenamic acid could be beneficial 
for AD by targeting essential pathological mediators within the disease process. 
Further behavioral tests in AD animal models are necessary to determine the 
relationship between the molecular changes and cognitive improvement. 
Moreover, the connection between AP lowering and plaque burden needs to be 
examined. More research is needed in order to reveal the exact mechanism by 
which tolfenamic acid affects AD related proteins and the consequential effect on 
behavior and plaque pathology. 
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